Aspire生物制药在满足股权要求后重新获得纳斯达克合规，避免了退市。 Aspire Biopharma regained Nasdaq compliance and avoids delisting after meeting equity requirements.

Aspire Biopharma(ASBP)恢复了对Nasdaq上市规则的全面遵守,在先前满足了1.0美元的最低投标价格之后,满足了250万美元的股东股本要求。 Aspire Biopharma (ASBP) has regained full compliance with Nasdaq listing rules, meeting the $2.5 million stockholders' equity requirement after previously satisfying the $1.00 minimum bid price. 该公司的股票将保留在Nasdaq上市, 但直到2027年2月18日, The company’s stock will remain listed on Nasdaq, though it will be under a one-year "Panel Monitor" until February 18, 2027. 在此期间，未能维持股权门槛将触发除牌听证会。 During this period, failure to maintain the equity threshold would trigger a delisting hearing. 艾斯普尔开发了以语言下药物递送技术,旨在通过消化系统快速,精确地递送药物,并有可能在各种治疗和补充剂中使用. Aspire develops sublingual drug delivery technology aimed at rapid, precise medication delivery, bypassing the digestive system, with potential use across various therapeutics and supplements. 释放中的前瞻性声明涉及风险,不应被视为保障。 Forward-looking statements in the release involve risks and should not be viewed as guarantees.